- Home
- MLKN vs VOR Comparison
MLKN vs VOR Comparison
Compare MLKN & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLKN | VOR |
|---|---|---|
| Founded | 1905 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MLKN | VOR |
|---|---|---|
| Price | $23.84 | $22.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $45.33 |
| AVG Volume (30 Days) | 655.9K | ★ 813.3K |
| Earning Date | 03-25-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.71% | N/A |
| EPS Growth | ★ 344.44 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $3,841,700,000.00 | N/A |
| Revenue This Year | $5.94 | N/A |
| Revenue Next Year | $3.78 | N/A |
| P/E Ratio | $18.20 | ★ N/A |
| Revenue Growth | ★ 4.68 | N/A |
| 52 Week Low | $13.77 | $1.90 |
| 52 Week High | $24.71 | $49.95 |
Technical Indicators
Market Signals| Indicator | MLKN | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 61.55 | 63.07 |
| Support Level | $18.05 | $11.62 |
| Resistance Level | $24.71 | N/A |
| Average True Range (ATR) | 0.80 | 1.45 |
| MACD | -0.11 | 0.06 |
| Stochastic Oscillator | 68.39 | 75.32 |
Price Performance
Historical ComparisonAbout MLKN MillerKnoll Inc.
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.